EUVIMEDEUVIMED entdecken
Crossref

Clinical Experience with [ 225 Ac]Ac-PSMA Treatment in Patients with [ 177 Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer

Nalan Alan-Selcuk, Gamze Beydagi, Emre Demirci, Meltem Ocak, Serkan Celik, Bala B Oven, Turkay Toklu, Ipek Karaaslan, Kaan Akcay, Omer Sonmez, Levent Kabasakal

Journal of Nuclear Medicine · 2023-10 · 64 (10) · 1574-1580

DOI: 10.2967/jnumed.123.265546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 24.08.2023. Verfasst von Nalan Alan-Selcuk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC) who do not respond to [177Lu]Lu-PSMA therapy, there are limited treatment options. Clinical results obtained with [225Ac]Ac-PSMA are promising. We retrospectively analyzed the outcomes of patients treated with [225Ac]Ac-PSMA between December 2018 and October 2022.

Methods

We evaluated the treatment results of 23 patients (mean age, 70.3 ± 8.8 y) with mCRPC who were refractory to treatment with [177Lu]Lu-PSMA (2-9 cycles). The safety profile was assessed according to Common Technology Criteria for Adverse Events version 5.0. Treatment efficacy was assessed using prostate-specific membrane antigen PET progression criteria and prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 2 criteria after the first cycle of [225Ac]Ac-PSMA treatment.

Results

All patients received androgen-deprivation therapy, whereas 22 (96%) and 19 (83%) patients received chemotherapy and second-generation antiandrogen therapy, respectively. One patient received 4 cycles, 2 received 3 cycles, 8 received 2 cycles, and 12 received 1 cycle of [225Ac]Ac-PSMA. The median interval between cycles was 13 wk (range, 8-28 wk). [225Ac]Ac-PSMA was administered with a mean activity of 7.6 MBq (range, 6.2-10.0 MBq) in each cycle. Patients were at an advanced stage of disease, and tumor burden was very high. Although the best PSA response was observed in 5 patients (26%) after [225Ac]Ac-PSMA treatment, there was at least some level of decline in PSA observed in 11 patients (58%; n = 19). Treatment response was assessed in patients who underwent [68Ga]Ga-PSMA PET/CT imaging. After the first cycle of treatment (n = 18), 50% of patients (n = 9) showed disease progression according to prostate-specific membrane antigen PET progression criteria, and the disease control rate was calculated to be 50%. Median progression-free survival was 3.1 mo, and median overall survival was 7.7 mo. Grade 3 hematologic toxicity occurred in 1 patient, and grade 3 nephrotoxicity was observed in another patient. Parotid SUVmax decreased by 33%, although all patients complained of dry mouth before treatment.

Conclusion

We observed that [225Ac]Ac-PSMA therapy was safe and showed potential even in cases with advanced-stage mCRPC in which all other treatment options were completed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansMiddle AgedAgedProstate-Specific AntigenPositron Emission Tomography Computed TomographyRetrospective StudiesAndrogen AntagonistsRadiopharmaceuticalsDipeptidesTreatment OutcomeHeterocyclic Compounds, 1-RingLutetium

Stichwörter der Autor:innen

PSMA[177Lu]Lu-PSMA[225Ac]Ac-PSMAactinium-targeted α-therapyprostate cancer

Substanzen

Prostate-Specific AntigenAndrogen AntagonistsRadiopharmaceuticalsDipeptidesHeterocyclic Compounds, 1-RingLutetium

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
  • Department of Radiology, University of Missouri, Columbia, Missouri.
  • Molecular Imaging and Theranostics Center, University of Missouri, Columbia, Missouri.
  • Department of Medical Oncology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
  • Department of Physics, Yeditepe University, Istanbul, Turkey; and.
  • Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey; lkabasakal@tsnm.org.

Zitieren

APA

Alan-Selcuk, N., Beydagi, G., Demirci, E., Ocak, M., Celik, S., Oven, B. B., Toklu, T., Karaaslan, I., Akcay, K., Sonmez, O., & Kabasakal, L. (2023). Clinical Experience with [ 225 Ac]Ac-PSMA Treatment in Patients with [ 177 Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 64(10), 1574-1580. https://doi.org/10.2967/jnumed.123.265546

Vancouver

Alan-Selcuk N, Beydagi G, Demirci E, Ocak M, Celik S, Oven BB, et al. Clinical Experience with [ 225 Ac]Ac-PSMA Treatment in Patients with [ 177 Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2023;64(10):1574-1580. doi:10.2967/jnumed.123.265546

BibTeX
@article{AlanSelcuk2023,
  author = {Alan-Selcuk, Nalan and Beydagi, Gamze and Demirci, Emre and Ocak, Meltem and Celik, Serkan and Oven, Bala B and Toklu, Turkay and Karaaslan, Ipek and Akcay, Kaan and Sonmez, Omer and Kabasakal, Levent},
  title = {Clinical Experience with [ 225 Ac]Ac-PSMA Treatment in Patients with [ 177 Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {10},
  pages = {1574--1580},
  doi = {10.2967/jnumed.123.265546}
}
Kostenlos starten →